{
  "title": "New Patient Outcome Assessed in Psoriasis Biologic Trial - Medscape",
  "url": "https://www.medscape.com/viewarticle/move-toward-assessing-well-being-psoriasis-biologic-2025a1000rgw",
  "summary": [
    {
      "type": "bullet",
      "text": "The study found that after 16 weeks of treatment with tildrakizumab, patients' WHO-5 Well-Being Index scores increased significantly from a mean baseline of 53.7 to 63.2, indicating improvements in psychological well-being as the score approached levels typical for healthy individuals."
    },
    {
      "type": "bullet",
      "text": "At 52 weeks post-treatment initiation, despite continuing skin clearance improvements (mean PASI scores of 1.5 and 1.3), patients' WHO-5 scores had plateaued at a mean of 65.9, suggesting that while physical symptoms may be well-controlled, psychological recovery might continue to evolve beyond the initial phase."
    },
    {
      "type": "bullet",
      "text": "The trial highlighted a complex relationship between physical and mental health recovery: 29.5% of patients experienced delayed WHO-5 recovery scores at 16 weeks despite achieving skin clearance, underscoring the importance of considering both dimensions in treatment outcomes for chronic conditions like psoriasis."
    }
  ],
  "model": "granite4:tiny-h"
}